1. Home
  2. SAGE vs HKD Comparison

SAGE vs HKD Comparison

Compare SAGE & HKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • HKD
  • Stock Information
  • Founded
  • SAGE 2010
  • HKD 2003
  • Country
  • SAGE United States
  • HKD France
  • Employees
  • SAGE N/A
  • HKD N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • HKD Finance: Consumer Services
  • Sector
  • SAGE Health Care
  • HKD Finance
  • Exchange
  • SAGE Nasdaq
  • HKD Nasdaq
  • Market Cap
  • SAGE 444.1M
  • HKD 447.7M
  • IPO Year
  • SAGE 2014
  • HKD 2022
  • Fundamental
  • Price
  • SAGE $7.50
  • HKD $2.34
  • Analyst Decision
  • SAGE Hold
  • HKD
  • Analyst Count
  • SAGE 20
  • HKD 0
  • Target Price
  • SAGE $10.56
  • HKD N/A
  • AVG Volume (30 Days)
  • SAGE 1.6M
  • HKD 278.7K
  • Earning Date
  • SAGE 04-24-2025
  • HKD 01-01-0001
  • Dividend Yield
  • SAGE N/A
  • HKD N/A
  • EPS Growth
  • SAGE N/A
  • HKD 1.75
  • EPS
  • SAGE N/A
  • HKD 0.23
  • Revenue
  • SAGE $41,243,000.00
  • HKD $20,445,000.00
  • Revenue This Year
  • SAGE $105.47
  • HKD N/A
  • Revenue Next Year
  • SAGE $67.53
  • HKD N/A
  • P/E Ratio
  • SAGE N/A
  • HKD $10.10
  • Revenue Growth
  • SAGE N/A
  • HKD N/A
  • 52 Week Low
  • SAGE $4.62
  • HKD $2.20
  • 52 Week High
  • SAGE $22.18
  • HKD $5.80
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 60.15
  • HKD 37.08
  • Support Level
  • SAGE $7.07
  • HKD $2.20
  • Resistance Level
  • SAGE $7.64
  • HKD $2.78
  • Average True Range (ATR)
  • SAGE 0.27
  • HKD 0.13
  • MACD
  • SAGE 0.00
  • HKD -0.02
  • Stochastic Oscillator
  • SAGE 78.74
  • HKD 23.33

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About HKD AMTD Digital Inc. (every five of which represent two)

AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. The company integrates various digital businesses using its AMTD SpiderNet ecosystem. Its reportable segments are; digital solutions services financial services; digital solutions services non-financial services, hotel operations, hospitality and VIP services, digital media, content and marketing services, and others. The company generates maximum revenue by providing financial digital solutions through its AMTD Risk Solutions, a digital insurance brokerage platform, and PolicyPal which is a digital insurance technology platform. Geographically, the company generates maximum revenue from Hong Kong and the rest from Canada and Singapore.

Share on Social Networks: